Literature DB >> 8872133

Relationship between prothrombin activation fragment F1 + 2 and serum cholesterol.

C Alessandri1, S Basili, M Maurelli, D Bracaglia, P Andreozzi, M Pergolini, C Cordova.   

Abstract

Plasma levels of fibrinogen, factor VIIc and prothrombin fragment F1 + 2, a marker of thrombin generation in vivo, were studied in 68 subjects with serum total cholesterol (TC) levels between 135 and 349 mg/dl but without clinical evidence of cardiovascular disease and other atherosclerotic risk factors. F1 + 2 plasma levels were directly correlated with TC (p < 0.0004), low-density lipoprotein cholesterol (LDL-C; p < 0.0018) and factor VIIc (p < 0.024). Thirty-five subjects with TC greater than 249 mg/dl (median value of the whole group) showed higher levels of F1 + 2 (p < 0.0001) and fibrinogen (p < 0.0015) than those with TC lower than 249 mg/dl. In subjects with TC > 249 mg/dl and F1 + 2 > 1.2 nM (median value of the whole group), a cholesterol-lowering drug (simvastatin) was able to reduce F1 + 2 (p < 0.009) as well as TC and LDL-C. This study shows a relationship between serum cholesterol and the rate of thrombin generation supporting the hypothesis that a hypercoagulable state may occur in hypercholesterolemic subjects before the onset of clinical evidence of atherosclerotic cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872133     DOI: 10.1159/000217210

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  3 in total

1.  Statins as first-line therapy for acute coronary syndrome?

Authors:  Petr Ostadal
Journal:  Exp Clin Cardiol       Date:  2012

2.  Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?

Authors:  Petr Ostadal; David Alan; Jiri Vejvoda
Journal:  Exp Clin Cardiol       Date:  2005

Review 3.  Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.

Authors:  Robert Krysiak; Boguslaw Okopień; Zbigniew Herman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.